- Home
- BH vs IOVA Comparison
BH vs IOVA Comparison
Compare BH & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BH | IOVA |
|---|---|---|
| Founded | 1934 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.9M | 968.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BH | IOVA |
|---|---|---|
| Price | $299.34 | $2.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | 103.0K | ★ 19.7M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.91 | N/A |
| Revenue | ★ $386,507,000.00 | $250,425,000.00 |
| Revenue This Year | N/A | $65.15 |
| Revenue Next Year | N/A | $58.47 |
| P/E Ratio | $441.44 | ★ N/A |
| Revenue Growth | 6.87 | ★ 175.62 |
| 52 Week Low | $195.05 | $1.64 |
| 52 Week High | $381.83 | $9.38 |
Technical Indicators
Market Signals| Indicator | BH | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 47.35 |
| Support Level | $266.53 | $2.09 |
| Resistance Level | $306.88 | $2.55 |
| Average True Range (ATR) | 18.00 | 0.20 |
| MACD | -1.60 | -0.00 |
| Stochastic Oscillator | 44.23 | 23.08 |
Price Performance
Historical ComparisonAbout BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.